Document Detail


Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
MedLine Citation:
PMID:  19355809     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dual antiplatelet therapy with a thienopyridine in combination with aspirin for 1 to 6 months after stenting has been recommended by the manufacturers to reduce ischemic cardiovascular events and thrombosis after coronary stenting, whereas the current leading guidelines recommend dual antiplatelet therapy for 12 months following percutaneous coronary intervention in all patients not at high risk of bleeding. Despite the established benefits of dual antiplatelet therapy in acute coronary syndrome (ACS) patients, there are concerns regarding the risk of major bleeding. The risks, benefits, and complexity identified in these interventional trials are communicated in this article to enable well-informed therapeutic decisions. Thienopyridine nonresponsiveness and variability of response are emerging as significant concerns in ACS patients that may lead to poor long-term cardiovascular outcomes. Current research on thienopyridine responsiveness and evidence-based mechanisms for overcoming thienopyridine nonresponsiveness are discussed. In addition, adherence to dual antiplatelet therapy is critical but difficult to achieve, and a considerable proportion of patients (1 of 7) discontinue therapy before 30 days of drug-eluting stent implantation. It has been established that premature discontinuation of thienopyridine therapy is associated with a marked increase in the risk of stent thrombosis (and consequently myocardial infarction and/or death) and is the leading independent predictor of stent thrombosis in multivariate analyses. The factors related to premature cessation of thienopyridine therapy are listed with recommendations for minimizing the complications arising as a result of premature discontinuation.
Authors:
Jason Cross
Related Documents :
15068949 - Aortoiliac insufficiency: long-term experience with stent placement for treatment.
8565889 - Metal stents for palliation of rectal carcinoma: a preliminary report on 12 patients.
7510599 - Prolonged survival after high-dose rate endobronchial radiation for malignant airway ob...
8539359 - Wallstents for the treatment of extrinsic malignant ureteral obstruction: midterm results.
15951939 - Prospective randomized study of t-tube versus biliary stent for common bile duct decomp...
17099019 - Performance of a self-expanding silicone stent in palliation of benign airway conditions.
18216569 - Therapeutic keratoplasty for corneal perforation: clinical results and complications.
2106819 - Topical flurbiprofen in intraocular surgery on diabetic and nondiabetic patients.
15740939 - Manubriotomy versus median sternotomy in thymectomy for myasthenia gravis. evaluation o...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The American journal of managed care     Volume:  15     ISSN:  1936-2692     ISO Abbreviation:  Am J Manag Care     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-04-09     Completed Date:  2009-11-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9613960     Medline TA:  Am J Manag Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S48-53     Citation Subset:  H    
Affiliation:
Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, 19 Foster St, Ste 510, Worcester, MA 01608, USA. jason.cross@mcphs.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy*,  mortality,  therapy
Angioplasty, Transluminal, Percutaneous Coronary*
Aspirin / therapeutic use*
Fibrinolytic Agents / therapeutic use
Humans
Platelet Aggregation Inhibitors / therapeutic use*
Practice Guidelines as Topic*
Pyridines / therapeutic use*
Stents
Time Factors
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Pyridines; 0/thienopyridine; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and ...
Next Document:  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders...